According to Future Market Insights (FMI) analysis in a recent market survey, the global cervical cancer screening market was valued at US$ 1.4 Billion in 2022 and is expected to reach US$ 5.7 Billion by 2033.
Market Outlook:
| Data Points | Market Insights |
|---|---|
| Market Value 2022 | US$ 1.4 Billion |
| Market Value 2023 | US$ 1.6 Billion |
| Market Value 2033 | US$ 5.7 Billion |
| CAGR 2023 to 2033 | 13.7% |
| Share of Top 5 Countries | 50.2% |
| Key Players | The key players in the cervical cancer screening market are Abbott Laboratories, Becton, Dickinson and Company, F. Hoffmann-La Roche, Hologic, Inc., QIAGEN, Bio-Rad Laboratories, Inc., Thermo Fisher Scientific Inc., Promega Corporation, Sysmex Inostics Inc., Danaher (Cepheid), FUJIREBIO, Everlywell, Inc., and Sansure Biotech Inc. |
Cervical screening encompasses various methods such as cervical cytology (Pap test or Pap smear), human papillomavirus (HPV) testing, or a combination of both. It is recommended that most women undergo routine cervical cancer screening to ensure early detection and appropriate preventive measures. A Pap test can occasionally reveal diseases like inflammation or infection that are not malignancy. The HPV/Pap co-test examines cervical cell alterations as well as high-risk HPV using both an HPV test and a Pap test.
Overall, the increasing screening for the detection of cervical cancer will boost the market in the coming years.
Don't pay for what you don't need
Customize your report by selecting specific countries or regions and save 30%!
Sales of the cervical cancer screening market grew at a CAGR of 7.4% from 2012 to 2022. The cervical cancer screening market contributes a 0.7% revenue share to the global cancer diagnostics market in 2022 which was valued at US$ 191.0 Billion.
About 70% of cervical cancer occurrences globally are caused by HPV strains 16 and 18. It is now possible to prevent HPV 16 and 18 infections, which has the potential to lower the prevalence of anogenital and cervical malignancies. Squamous intraepithelial lesion (SIL) and cervical intraepithelial neoplasia (CIN) are widely used terms to describe the presence of abnormal squamous cell growth in the cervix, indicating a precancerous condition.
On 4th March 2023, International Agency for Research on Cancer mentioned that more than 300 000 women per year die from cervical cancer, which is currently the fourth most prevalent cancer in women. In low- and middle-income nations, cervical cancer fatalities account for almost 90% of all deaths.
Other than the Pap test and HPV test, in low-resource situations, visual examination with acetic acid (VIA) can replace cytology-based screening.
Considering this, FMI expects the global cervical cancer screening market to grow at a CAGR of 13.7% through the forecasted years.
The objective of cervical cancer screening is to identify precancerous changes in cervical cells that can be effectively treated to prevent the progression of cervical cancer.
New advancements in human papillomavirus (HPV) DNA testing, Papanicolaou test technology, and updates to the Bethesda terminology for cervical cytology have led to changes in the management of abnormal Pap tests. A recent clinical trial has provided information that includes a reduction in the number of colposcopies required by 50% in certain cases. Femtech is driving a significant transformation in women's healthcare.
Leading manufacturers are focusing on affordable testing and also reducing the overall cost of treatment with the help of technologically advanced screening tests. This creates an opportunity for the market to expand exponentially.
Principal Consultant
The Pap test is a crucial element of a woman's overall health. It assists in the early detection of cervix precancerous cells before they transform into malignant cells. However, the Pap test has some limitations as a cervical cancer prevention method.
Traditional cervical cancer screening methods primarily focus on examining the end cervical canal. Patients often undergo an invasive procedure called a colposcopy when an abnormal Pap screening is observed. This involves visualizing cervical cancer and collecting tissue samples. However, for many years, the only available instruments for tissue collection were conventional ones such as brushes or a Kevorkian curette.
The Pap test's primary flaw is that, like many other tests, it is unable to provide accurate results. In the event that a Pap test yields a false positive result, the cervix may contain precancerous cells.
The USA dominated the global market with a value share of around 25.1% in 2022.
The American College of Obstetricians and Gynecologists (ACOG), the American Society for Colposcopy and Cervical Pathology (ASCCP), and the Society of Gynecologic Oncologists SGO nonetheless advise starting cervical cancer screening at age 21. Obstetricians-gynecologists and other healthcare practitioners should continue to strongly advise eligible people to get the HPV vaccine and emphasize its advantages and safety as another key method of preventing cervical cancer.
The demand for cervical cancer screening will increase with the assistance of awareness created by the established player and create an area for diagnostics testing labs to provide low-cost health checkups, which will drive the expansion of the market.
Japan is projected to be the most attractive market in cervical cancer screening and holds a market share of 7.6% in the global market in 2022. The Japanese government is working actively for the benefit of women’s welfare.
Germany dominated the global market for cervical cancer screening and accounted for 6.3% of the market share in 2022.
Germany conducted a screening program for the prevention of cervical cancer in women from the age of 35 years with the collaboration of Statutory Health Insurance (GKV) to understand the dynamics of cervical cancer screening. A groundbreaking implementation of HPV co-testing and cytology in a substantial population of women aged 35 and above in Germany suggests that this approach could enhance cervical cancer prevention, particularly when combined with liquid-based computer-assisted cytology examinations that incorporate patients' HPV status.
The presence of prominent players in Germany will influence the overall market.
Get the data you need at a Fraction of the cost
Personalize your report by choosing insights you need
and save 40%!
The human papillomavirus (HPV) segment held the major chunk of 75.0% of the global market by the end of 2022.
The main factor causing cervical cancer is HPV. The majority of occurrences of cervical cancer are caused by high-risk HPV strains like HPV 16 and 18, which account for about 70% of cases, as per WHO 2022 insights.
Overall, human papillomavirus (HPV) is a widely adopted test that helps in screening for cervical cancer.
Squamous cell carcinomas were the predominant segment with a market share of 57.5% in the global market by the end of 2022.
As per the Cancer Research UK 2020 statistics, nearly 70% to 90% of all occurrences of cervical cancer are squamous cell carcinoma, making it the most prevalent kind. The squamous cells that border the outside of the cervix give rise to this type of cancer.
As it is the predominant occurring cervical cancer it holds the highest market share in the global market.
The 31 - 65 years age group accounted for a revenue share of 61.7% in the global market at the end of 2022.
The human papillomavirus (HPV), particularly HPV types 16 and 18 often acquired during sexual activity. The virus is often cleared by the immune system within a couple of years, but occasionally the infection lingers and raises the risk of cervical cancer.
Between the ages of 31 and 65, those who contracted HPV may start to feel the effects of a persistent infection, which can result in the development of cervical cancer. Hence ages of 31 and 65 hold a significant share of the global market.
The hospital segment accounted for a revenue share of 39.7% in the global market at the end of 2022.
Hospitals typically have specialized departments or clinics dedicated to women's health, including cervical cancer screening. These facilities ensure that the testing is conducted in a controlled and efficient manner.
Overall, hospitals offer a setting that encourages interaction between healthcare practitioners with various expertise, making it the lucrative segment of end users.
Among the primary approaches used by manufacturers to get a competitive edge in the market are pricing strategies, market strategies, technical advancements, regulatory compliance, and acquisition and distribution agreements with other businesses to expand their business.
For instance:
Similarly, recent developments have been tracked by the team at Future Market Insights related to companies in cervical cancer screening market space, which are available in the full report
| Attribute | Details |
|---|---|
| Forecast Period | 2023 to 2033 |
| Historical Data Available for | 2012 to 2022 |
| Market Analysis | USD Million for Value |
| Key Regions Covered | North America; Latin America; Europe; South Asia; East Asia; Oceania; Middle East; and Africa (MEA) |
| Key Countries Covered | USA, Canada, Brazil, Mexico, Argentina, Germany, UK, France, Italy, Spain, Russia, BENELUX, Nordics, China, Japan, South Korea, India, Thailand, Indonesia, Malaysia, Australia, New Zealand, Türkiye, South Africa, North Africa, and GCC Countries |
| Key Segments Covered | Test, Cancer, Age Group, End User, and Region |
| Key Companies Profiled | Abbott Laboratories; Becton, Dickinson, and Company; F. Hoffmann-La Roche; Hologic, Inc.; QIAGEN; Bio-Rad Laboratories, Inc.; Thermo Fisher Scientific Inc.; Promega Corporation; Sysmex Inostics Inc.; Danaher (Cepheid); FUJIREBIO; Everlywell, Inc.; Sansure Biotech Inc. |
| Report Coverage | Market Forecast, Competition Intelligence, DROT Analysis, Market Dynamics and Challenges, Strategic Growth Initiatives |
| Customization & Pricing | Available upon Request |
The hospital holds high revenue potential.
The United States, Japan, and Germany are advancing in healthcare.
The market is forecast to register a CAGR of 13.7% through 2033.
During 2018 to 2022, the market registered a CAGR of 7.4%.
The popularity of new advanced test technologies increases current market trends.
1. Executive Summary
1.1. Global Market Outlook
1.2. Demand Side Trends
1.3. Supply Side Trends
1.4. Analysis and Recommendations
2. Market Overview
2.1. Market Coverage / Taxonomy
2.2. Market Definition / Scope / Limitations
2.3. Inclusion and Exclusions
3. Key Market Trends
3.1. Key Trends Impacting the Market
3.2. Test Innovation/ Development Trends
4. Value-Added Insights
4.1. Epidemiology of Cervical Cancer
4.2. Distribution Channel Analysis
4.3. Regulatory Scenario
5. Market Background
5.1. Macro-Economic Factors
5.1.1. Global GDP Growth Outlook
5.1.2. Global Healthcare Expenditure Outlook
5.1.3. Global Cancer Diagnostics Market Outlook
5.2. Forecast Factors - Relevance & Impact
5.2.1. Cervical Cancer Epidemiology
5.2.2. Regulatory Framework
5.2.3. Recent Advancements In Technology
5.2.4. Clinical, and Economic Impacts
5.2.5. New Product Launches and Development
5.2.6. Top Companies Historic Growth
5.2.7. Increasing Rate of Screening Adoption
5.2.8. Government Funding
5.3. Market Dynamics
5.3.1. Drivers
5.3.2. Restraints
5.3.3. Opportunity Analysis
6. COVID-19 Crisis Analysis
6.1. 2022 Market Scenario
6.2. COVID-19 and Impact Analysis
6.2.1. By Test
6.2.2. By Cancer
6.2.3. By End User
6.2.4. By Age Group
6.2.5. By Region
7. Global Market Demand (in Value or Size in US$ Mn) Analysis 2012 to 2022 and Forecast, 2023 to 2033
7.1. Historical Market Value (US$ Million) Analysis, 2012 to 2022
7.2. Current and Future Market Value (US$ Million) Projections, 2023 to 2033
7.2.1. Y-o-Y Growth Trend Analysis
7.2.2. Absolute $ Opportunity Analysis
8. Global Market Analysis 2012 to 2022 and Forecast 2023 to 2033, By Test
8.1. Introduction / Key Findings
8.2. Historical Market Size (US$ Million) Analysis by Test, 2012 to 2022
8.3. Current and Future Market Size (US$ Million) Analysis and Forecast by Test, 2023 to 2033
8.3.1. Cervical Cytology (Pap smear)
8.3.2. Human Papillomavirus (HPV)
8.3.3. Visual inspection with acetic acid (VIA)
8.4. Market Attractiveness Analysis by Test
9. Global Market Analysis 2012 to 2022 and Forecast 2023 to 2033, By Cancer
9.1. Introduction / Key Findings
9.2. Historical Market Size (US$ Million) Analysis by Cancer, 2012 to 2022
9.3. Current and Future Market Size (US$ Million) Analysis and Forecast by Cancer, 2023 to 2033
9.3.1. Squamous Cell Carcinomas
9.3.2. Adenocarcinomas
9.4. Market Attractiveness Analysis by Cancer
10. Global Market Analysis 2012 to 2022 and Forecast 2023 to 2033, By Age Group
10.1. Introduction / Key Findings
10.2. Historical Market Size (US$ Million) Analysis by Age Group, 2012 to 2022
10.3. Current and Future Market Size (US$ Million) Analysis and Forecast by Age Group, 2023 to 2033
10.3.1. 21 - 30 Years
10.3.2. 31 - 65 Years
10.4. Market Attractiveness Analysis by Age Group
11. Global Market Analysis 2012 to 2022 and Forecast 2023 to 2033, By End User
11.1. Introduction / Key Findings
11.2. Historical Market Size (US$ Million) Analysis by End User, 2012 to 2022
11.3. Current and Future Market Size (US$ Million) Analysis and Forecast by End User, 2023 to 2033
11.3.1. Hospitals
11.3.2. Cancer Research Institutes
11.3.3. Specialty Clinics
11.3.4. Diagnostic Laboratories
11.4. Market Attractiveness Analysis by End User
12. Global Market Analysis 2012 to 2022 and Forecast 2023 to 2033, By Region
12.1. Introduction
12.2. Historical Market Size (US$ Million) Analysis by Region, 2012 to 2022
12.3. Current and Future Market Size (US$ Million) Analysis and Forecast by Region, 2023 to 2033
12.3.1. North America
12.3.2. Latin America
12.3.3. Europe
12.3.4. East Asia
12.3.5. South Asia
12.3.6. Oceania
12.3.7. Middle East and Africa
12.4. Market Attractiveness Analysis by Region
13. North America Market Analysis 2012 to 2022 and Forecast 2023 to 2033
13.1. Introduction
13.2. Historical Market Size (US$ Million) Trend Analysis by Market Taxonomy, 2012 to 2022
13.3. Current and Future Market Size (US$ Million) Analysis and Forecast by Market Taxonomy, 2023 to 2033
13.3.1. By Country
13.3.1.1. United States of America
13.3.1.2. Canada
13.3.2. By Test
13.3.3. By Cancer
13.3.4. By End User
13.3.5. By Age Group
13.4. Market Attractiveness Analysis
13.4.1. By Country
13.4.2. By Test
13.4.3. By Cancer
13.4.4. By End User
13.4.5. By Age Group
13.5. Market Trends
13.6. Key Market Participants - Intensity Mapping
13.7. Drivers and Restraints - Impact Analysis
13.8. Country-Level Analysis & Forecast
13.8.1. United States of America Market
13.8.1.1. Introduction
13.8.1.2. Market Analysis and Forecast by Market Taxonomy
13.8.1.2.1. By Test
13.8.1.2.2. By Cancer
13.8.1.2.3. By End User
13.8.1.2.4. By Age Group
13.8.2. Canada Market
13.8.2.1. Introduction
13.8.2.2. Market Analysis and Forecast by Market Taxonomy
13.8.2.2.1. By Test
13.8.2.2.2. By Cancer
13.8.2.2.3. By End User
13.8.2.2.4. By Age Group
14. Latin America Market Analysis 2012 to 2022 and Forecast 2023 to 2033
14.1. Introduction
14.2. Historical Market Size (US$ Million) Trend Analysis by Market Taxonomy, 2012 to 2022
14.3. Current and Future Market Size (US$ Million) Analysis and Forecast by Market Taxonomy, 2023 to 2033
14.3.1. By Country
14.3.1.1. Mexico
14.3.1.2. Brazil
14.3.1.3. Argentina
14.3.1.4. Rest of Latin America
14.3.2. By Test
14.3.3. By Cancer
14.3.4. By End User
14.3.5. By Age Group
14.4. Market Attractiveness Analysis
14.4.1. By Country
14.4.2. By Test
14.4.3. By Cancer
14.4.4. By End User
14.4.5. By Age Group
14.5. Market Trends
14.6. Key Market Participants - Intensity Mapping
14.7. Drivers and Restraints - Impact Analysis
14.8. Country-Level Analysis & Forecast
14.8.1. Mexico Market
14.8.1.1. Introduction
14.8.1.2. Market Analysis and Forecast by Market Taxonomy
14.8.1.2.1. By Test
14.8.1.2.2. By Cancer
14.8.1.2.3. By End User
14.8.1.2.4. By Age Group
14.8.2. Brazil Market
14.8.2.1. Introduction
14.8.2.2. Market Analysis and Forecast by Market Taxonomy
14.8.2.2.1. By Test
14.8.2.2.2. By Cancer
14.8.2.2.3. By End User
14.8.2.2.4. By Age Group
14.8.3. Argentina Market
14.8.3.1. Introduction
14.8.3.2. Market Analysis and Forecast by Market Taxonomy
14.8.3.2.1. By Test
14.8.3.2.2. By Cancer
14.8.3.2.3. By End User
14.8.3.2.4. By Age Group
15. Europe Market Analysis 2012 to 2022 and Forecast 2023 to 2033
15.1. Introduction
15.2. Historical Market Size (US$ Million) Trend Analysis by Market Taxonomy, 2012 to 2022
15.3. Current and Future Market Size (US$ Million) Analysis and Forecast by Market Taxonomy, 2023 to 2033
15.3.1. By Country
15.3.1.1. United Kingdom
15.3.1.2. Germany
15.3.1.3. Italy
15.3.1.4. France
15.3.1.5. Spain
15.3.1.6. Russia
15.3.1.7. BENELUX
15.3.1.8. Rest of Europe
15.3.2. By Test
15.3.3. By Cancer
15.3.4. By End User
15.3.5. By Age Group
15.4. Market Attractiveness Analysis
15.4.1. By Country
15.4.2. By Test
15.4.3. By Cancer
15.4.4. By End User
15.4.5. By Age Group
15.5. Market Trends
15.6. Key Market Participants - Intensity Mapping
15.7. Drivers and Restraints - Impact Analysis
15.8. Country-Level Analysis & Forecast
15.8.1. United Kingdom Market
15.8.1.1. Introduction
15.8.1.2. Market Analysis and Forecast by Market Taxonomy
15.8.1.2.1. By Test
15.8.1.2.2. By Cancer
15.8.1.2.3. By End User
15.8.1.2.4. By Age Group
15.8.2. Germany Market
15.8.2.1. Introduction
15.8.2.2. Market Analysis and Forecast by Market Taxonomy
15.8.2.2.1. By Test
15.8.2.2.2. By Cancer
15.8.2.2.3. By End User
15.8.2.2.4. By Age Group
15.8.3. Italy Market
15.8.3.1. Introduction
15.8.3.2. Market Analysis and Forecast by Market Taxonomy
15.8.3.2.1. By Test
15.8.3.2.2. By Cancer
15.8.3.2.3. By End User
15.8.3.2.4. By Age Group
15.8.4. France Market
15.8.4.1. Introduction
15.8.4.2. Market Analysis and Forecast by Market Taxonomy
15.8.4.2.1. By Test
15.8.4.2.2. By Cancer
15.8.4.2.3. By End User
15.8.4.2.4. By Age Group
15.8.5. Spain Market
15.8.5.1. Introduction
15.8.5.2. Market Analysis and Forecast by Market Taxonomy
15.8.5.2.1. By Test
15.8.5.2.2. By Cancer
15.8.5.2.3. By End User
15.8.5.2.4. By Age Group
15.8.6. Russia Market
15.8.6.1. Introduction
15.8.6.2. Market Analysis and Forecast by Market Taxonomy
15.8.6.2.1. By Test
15.8.6.2.2. By Cancer
15.8.6.2.3. By End User
15.8.6.2.4. By Age Group
15.8.7. BENELUX Market
15.8.7.1. Introduction
15.8.7.2. Market Analysis and Forecast by Market Taxonomy
15.8.7.2.1. By Test
15.8.7.2.2. By Cancer
15.8.7.2.3. By End User
15.8.7.2.4. By Age Group
16. East Asia Market Analysis 2012 to 2022 and Forecast 2023 to 2033
16.1. Introduction
16.2. Historical Market Size (US$ Million) Trend Analysis by Market Taxonomy, 2012 to 2022
16.3. Current and Future Market Size (US$ Million) Analysis and Forecast by Market Taxonomy, 2023 to 2033
16.3.1. By Country
16.3.1.1. China
16.3.1.2. Japan
16.3.1.3. South Korea
16.3.2. By Test
16.3.3. By Cancer
16.3.4. By Age Group
16.3.5. By End User
16.4. Market Attractiveness Analysis
16.4.1. By Country
16.4.2. By Test
16.4.3. By Cancer
16.4.4. By End User
16.4.5. By Age Group
16.5. Market Trends
16.6. Key Market Participants - Intensity Mapping
16.7. Drivers and Restraints - Impact Analysis
16.8. Country-Level Analysis & Forecast
16.8.1. China Market
16.8.1.1. Introduction
16.8.1.2. Market Analysis and Forecast by Market Taxonomy
16.8.1.2.1. By Test
16.8.1.2.2. By Cancer
16.8.1.2.3. By End User
16.8.1.2.4. By Age Group
16.8.2. Japan Market
16.8.2.1. Introduction
16.8.2.2. Market Analysis and Forecast by Market Taxonomy
16.8.2.2.1. By Test
16.8.2.2.2. By Cancer
16.8.2.2.3. By End User
16.8.2.2.4. By Age Group
16.8.3. South Korea Market
16.8.3.1. Introduction
16.8.3.2. Market Analysis and Forecast by Market Taxonomy
16.8.3.2.1. By Test
16.8.3.2.2. By Cancer
16.8.3.2.3. By End User
16.8.3.2.4. By Age Group
17. South Asia Market Analysis 2012 to 2022 and Forecast 2023 to 2033
17.1. Introduction
17.2. Historical Market Size (US$ Million) Trend Analysis by Market Taxonomy, 2012 to 2022
17.3. Current and Future Market Size (US$ Million) Analysis and Forecast by Market Taxonomy, 2023 to 2033
17.3.1. By Country
17.3.1.1. India
17.3.1.2. Indonesia
17.3.1.3. Malaysia
17.3.1.4. Thailand
17.3.1.5. Rest of South Asia
17.3.2. By Test
17.3.3. By Cancer
17.3.4. By End User
17.3.5. By Age Group
17.4. Market Attractiveness Analysis
17.4.1. By Country
17.4.2. By Test
17.4.3. By Cancer
17.4.4. By End User
17.4.5. By Age Group
17.5. Market Trends
17.6. Key Market Participants - Intensity Mapping
17.7. Drivers and Restraints - Impact Analysis
17.8. Country-Level Analysis & Forecast
17.8.1. India Market
17.8.1.1. Introduction
17.8.1.2. Market Analysis and Forecast by Market Taxonomy
17.8.1.2.1. By Test
17.8.1.2.2. By Cancer
17.8.1.2.3. By End User
17.8.1.2.4. By Age Group
17.8.2. Indonesia Market
17.8.2.1. Introduction
17.8.2.2. Market Analysis and Forecast by Market Taxonomy
17.8.2.2.1. By Test
17.8.2.2.2. By Cancer
17.8.2.2.3. By End User
17.8.2.2.4. By Age Group
17.8.3. Malaysia Market
17.8.3.1. Introduction
17.8.3.2. Market Analysis and Forecast by Market Taxonomy
17.8.3.2.1. By Test
17.8.3.2.2. By Cancer
17.8.3.2.3. By End User
17.8.3.2.4. By Age Group
17.8.4. Thailand Market
17.8.4.1. Introduction
17.8.4.2. Market Analysis and Forecast by Market Taxonomy
17.8.4.2.1. By Test
17.8.4.2.2. By Cancer
17.8.4.2.3. By End User
17.8.4.2.4. By Age Group
18. Oceania Market Analysis 2012 to 2022 and Forecast 2023 to 2033
18.1. Introduction
18.2. Historical Market Size (US$ Million) Trend Analysis by Market Taxonomy, 2012 to 2022
18.3. Current and Future Market Size (US$ Million) Analysis and Forecast by Market Taxonomy, 2023 to 2033
18.3.1. By Country
18.3.1.1. Australia
18.3.1.2. New Zealand
18.3.2. By Test
18.3.3. By Cancer
18.3.4. By End User
18.3.5. By Age Group
18.4. Market Attractiveness Analysis
18.4.1. By Country
18.4.2. By Test
18.4.3. By Cancer
18.4.4. By End User
18.4.5. By Age Group
18.5. Market Trends
18.6. Key Market Participants - Intensity Mapping
18.7. Drivers and Restraints - Impact Analysis
18.8. Country-Level Analysis & Forecast
18.8.1. Australia Market
18.8.1.1. Introduction
18.8.1.2. Market Analysis and Forecast by Market Taxonomy
18.8.1.2.1. By Test
18.8.1.2.2. By Cancer
18.8.1.2.3. By End User
18.8.1.2.4. By Age Group
18.8.2. New Zealand Market
18.8.2.1. Introduction
18.8.2.2. Market Analysis and Forecast by Market Taxonomy
18.8.2.2.1. By Test
18.8.2.2.2. By Cancer
18.8.2.2.3. By End User
18.8.2.2.4. By Age Group
19. Middle East and Africa (Middle East and Africa) Market Analysis 2012 to 2022 and Forecast 2023 to 2033
19.1. Introduction
19.2. Historical Market Size (US$ Million) Trend Analysis by Market Taxonomy, 2012 to 2022
19.3. Current and Future Market Size (US$ Million) Analysis and Forecast by Market Taxonomy, 2023 to 2033
19.3.1. By Country
19.3.1.1. GCC Countries
19.3.1.2. Türkiye
19.3.1.3. South Africa
19.3.1.4. North Africa
19.3.1.5. Rest of Middle East and Africa
19.3.2. By Test
19.3.3. By Cancer
19.3.4. By End User
19.3.5. By Age Group
19.4. Market Attractiveness Analysis
19.4.1. By Country
19.4.2. By Test
19.4.3. By Cancer
19.4.4. By End User
19.4.5. By Age Group
19.5. Market Trends
19.6. Key Market Participants - Intensity Mapping
19.7. Drivers and Restraints - Impact Analysis
19.8. Country-Level Analysis & Forecast
19.8.1. GCC Countries Market
19.8.1.1. Introduction
19.8.1.2. Market Analysis and Forecast by Market Taxonomy
19.8.1.2.1. By Test
19.8.1.2.2. By Cancer
19.8.1.2.3. By End User
19.8.1.2.4. By Age Group
19.8.2. Türkiye Market
19.8.2.1. Introduction
19.8.2.2. Market Analysis and Forecast by Market Taxonomy
19.8.2.2.1. By Test
19.8.2.2.2. By Cancer
19.8.2.2.3. By End User
19.8.2.2.4. By Age Group
19.8.3. South Africa Market
19.8.3.1. Introduction
19.8.3.2. Market Analysis and Forecast by Market Taxonomy
19.8.3.2.1. By Test
19.8.3.2.2. By Cancer
19.8.3.2.3. By End User
19.8.3.2.4. By Age Group
19.8.4. North Africa Market
19.8.4.1. Introduction
19.8.4.2. Market Analysis and Forecast by Market Taxonomy
19.8.4.2.1. By Test
19.8.4.2.2. By Cancer
19.8.4.2.3. By End User
19.8.4.2.4. By Age Group
20. Market Structure Analysis
20.1. Market Analysis by Tier of Companies
20.2. Market Share Analysis of Top Players
20.3. Market Concentration
20.4. Market Presence Analysis
20.4.1. Regional Footprint of Players
20.4.2. Product Footprint by Players
20.4.3. Channel Footprint by Players
21. Competition Analysis
21.1. Competition Dashboard
21.2. Competition Deep Dive
21.2.1. Abbott Laboratories
21.2.1.1. Overview
21.2.1.2. Product Portfolio
21.2.1.3. Key Financials
21.2.1.4. Sales Footprint
21.2.1.5. SWOT Analysis
21.2.1.6. Key Developments
21.2.1.7. Strategy Overview
21.2.1.7.1. Channel Strategy
21.2.1.7.2. Marketing Strategy
21.2.1.7.3. Product Strategy
21.2.2. Becton, Dickinson, and Company,
21.2.2.1. Overview
21.2.2.2. Product Portfolio
21.2.2.3. Key Financials
21.2.2.4. Sales Footprint
21.2.2.5. SWOT Analysis
21.2.2.6. Key Developments
21.2.2.7. Strategy Overview
21.2.2.7.1. Channel Strategy
21.2.2.7.2. Marketing Strategy
21.2.2.7.3. Product Strategy
21.2.3. F. Hoffmann-La Roche
21.2.3.1. Overview
21.2.3.2. Product Portfolio
21.2.3.3. Key Financials
21.2.3.4. Sales Footprint
21.2.3.5. SWOT Analysis
21.2.3.6. Key Developments
21.2.3.7. Strategy Overview
21.2.3.7.1. Channel Strategy
21.2.3.7.2. Marketing Strategy
21.2.3.7.3. Product Strategy
21.2.4. Hologic, Inc.
21.2.4.1. Overview
21.2.4.2. Product Portfolio
21.2.4.3. Key Financials
21.2.4.4. Sales Footprint
21.2.4.5. SWOT Analysis
21.2.4.6. Key Developments
21.2.4.7. Strategy Overview
21.2.4.7.1. Channel Strategy
21.2.4.7.2. Marketing Strategy
21.2.4.7.3. Product Strategy
21.2.5. QIAGEN
21.2.5.1. Overview
21.2.5.2. Product Portfolio
21.2.5.3. Key Financials
21.2.5.4. Sales Footprint
21.2.5.5. SWOT Analysis
21.2.5.6. Key Developments
21.2.5.7. Strategy Overview
21.2.5.7.1. Channel Strategy
21.2.5.7.2. Marketing Strategy
21.2.5.7.3. Product Strategy
21.2.6. Bio-Rad Laboratories, Inc.
21.2.6.1. Overview
21.2.6.2. Product Portfolio
21.2.6.3. Key Financials
21.2.6.4. Sales Footprint
21.2.6.5. SWOT Analysis
21.2.6.6. Key Developments
21.2.6.7. Strategy Overview
21.2.6.7.1. Channel Strategy
21.2.6.7.2. Marketing Strategy
21.2.6.7.3. Product Strategy
21.2.7. Thermo Fisher Scientific Inc.
21.2.7.1. Overview
21.2.7.2. Product Portfolio
21.2.7.3. Key Financials
21.2.7.4. Sales Footprint
21.2.7.5. SWOT Analysis
21.2.7.6. Key Developments
21.2.7.7. Strategy Overview
21.2.7.7.1. Channel Strategy
21.2.7.7.2. Marketing Strategy
21.2.7.7.3. Product Strategy
21.2.8. Promega Corporation
21.2.8.1. Overview
21.2.8.2. Product Portfolio
21.2.8.3. Key Financials
21.2.8.4. Sales Footprint
21.2.8.5. SWOT Analysis
21.2.8.6. Key Developments
21.2.8.7. Strategy Overview
21.2.8.7.1. Channel Strategy
21.2.8.7.2. Marketing Strategy
21.2.8.7.3. Product Strategy
21.2.9. Sysmex Inostics Inc.
21.2.9.1. Overview
21.2.9.2. Product Portfolio
21.2.9.3. Key Financials
21.2.9.4. Sales Footprint
21.2.9.5. SWOT Analysis
21.2.9.6. Key Developments
21.2.9.7. Strategy Overview
21.2.9.7.1. Channel Strategy
21.2.9.7.2. Marketing Strategy
21.2.9.7.3. Product Strategy
21.2.10. Danaher (Cepheid)
21.2.10.1. Overview
21.2.10.2. Product Portfolio
21.2.10.3. Key Financials
21.2.10.4. Sales Footprint
21.2.10.5. SWOT Analysis
21.2.10.6. Key Developments
21.2.10.7. Strategy Overview
21.2.10.7.1. Channel Strategy
21.2.10.7.2. Marketing Strategy
21.2.10.7.3. Product Strategy
21.2.11. FUJIREBIO
21.2.11.1. Overview
21.2.11.2. Product Portfolio
21.2.11.3. Key Financials
21.2.11.4. Sales Footprint
21.2.11.5. SWOT Analysis
21.2.11.6. Key Developments
21.2.11.7. Strategy Overview
21.2.11.7.1. Channel Strategy
21.2.11.7.2. Marketing Strategy
21.2.11.7.3. Product Strategy
21.2.12. Everlywell, Inc.
21.2.12.1. Overview
21.2.12.2. Product Portfolio
21.2.12.3. Key Financials
21.2.12.4. Sales Footprint
21.2.12.5. SWOT Analysis
21.2.12.6. Key Developments
21.2.12.7. Strategy Overview
21.2.12.7.1. Channel Strategy
21.2.12.7.2. Marketing Strategy
21.2.12.7.3. Product Strategy
21.2.13. Sansure Biotech Inc.
21.2.13.1. Overview
21.2.13.2. Product Portfolio
21.2.13.3. Key Financials
21.2.13.4. Sales Footprint
21.2.13.5. SWOT Analysis
21.2.13.6. Key Developments
21.2.13.7. Strategy Overview
21.2.13.7.1. Channel Strategy
21.2.13.7.2. Marketing Strategy
21.2.13.7.3. Product Strategy
22. Assumptions and Acronyms Used
23. Research Methodology
Explore Healthcare Insights
View Reports
Cervical Cancer Screening Market
